Lexology April 25, 2022
Snell & Wilmer LLP

The US Food and Drug Administration (FDA) recently published a manual of policies and procedures (MAPP) outlining how the Office of Generic Drugs (OGD) will classify which new drugs and drug-device combination products are complex products for generic drug development purposes. The manual provides definitions and examples of complex drugs and drug-device combination products, as...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Roche Drug Scores Label Expansion for Earlier Use in Lung Cancer
Opinion: STAT+: How AI can help satisfy FDA’s drug, device diversity requirements
FDA wants to boost trial innovation with new center at CDER
Stelara biosimilar from Alvotech, Teva approved by FDA
Scopio Labs Receives FDA Clearance For AI-Driven Bone Marrow Analysis Application

Share This Article